目的观察益气活血解毒方对晚期卵巢癌患者免疫调节的影响。方法选择晚期上皮性卵巢癌患者40例,采用单臂开放式研究,所有患者连续4周服用益气活血解毒方(每次200 m L,每日2次)。采用流式细胞仪检测血中调节性T细胞CD4^+CD25^+、CD8^+CD28...目的观察益气活血解毒方对晚期卵巢癌患者免疫调节的影响。方法选择晚期上皮性卵巢癌患者40例,采用单臂开放式研究,所有患者连续4周服用益气活血解毒方(每次200 m L,每日2次)。采用流式细胞仪检测血中调节性T细胞CD4^+CD25^+、CD8^+CD28-及细胞毒T细胞CD8^+CD28^+数量的变化作为主要终点,观察疼痛、乏力、麻木等临床症状的变化作为次要终点。结果治疗结束后,患者调节性T细胞CD4^+CD25^+、CD8^+CD28^-细胞较治疗前明显降低(P<0.05),细胞毒T细胞CD8^+CD28^+数量较治疗前明显升高(P<0.05);除疼痛外,患者乏力、耳鸣、麻木、食欲不振、睡眠障碍、腹部不适、小便异常等症状明显改善(P<0.05)。结论益气活血解毒方能够明显改善晚期卵巢癌的免疫抑制,提高患者的生活质量。展开更多
OBJECTIVE:To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction(YHJD)on patients with advanced epithelial ovarian cancer(EOC).METHODS:All 330 enrolled participants diagnosed with stageⅢc EOC wer...OBJECTIVE:To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction(YHJD)on patients with advanced epithelial ovarian cancer(EOC).METHODS:All 330 enrolled participants diagnosed with stageⅢc EOC were randomly divided into two groups that received YHJD or a placebo.The primary end point was health-related quality of life(HRQL)measured by the functional assessment of cancer therapy-ovary cancer(FACT-O)questionnaire.The secondary end point was progression-free survival(PFS).RESULTS:A total of 299 participants completed the trial with 153 and 146 in YHJD and control groups,respectively.After 6 months of treatment,YHJD increased physical wellbeing(PWB),functional wellbeing(FWB),additional concerns(AC),and the trial outcome index(TOI)(P<0.05)by various degrees compared with the baseline.YHJD also had notable advantages over the placebo at 3 and 6 months in terms of PWB,FWB,AC(P<0.05),and TOI(P<0.01).In addition,YHJD had a significant advantage in terms of PFS compared with the placebo(21 vs18 months,P<0.05).No adverse events were reported.CONCLUSION:YHJD is an effective and safe choice as a complementary therapy to improve HRQL and prolong PFS of stageⅢc EOC patients.展开更多
文摘目的观察益气活血解毒方对晚期卵巢癌患者免疫调节的影响。方法选择晚期上皮性卵巢癌患者40例,采用单臂开放式研究,所有患者连续4周服用益气活血解毒方(每次200 m L,每日2次)。采用流式细胞仪检测血中调节性T细胞CD4^+CD25^+、CD8^+CD28-及细胞毒T细胞CD8^+CD28^+数量的变化作为主要终点,观察疼痛、乏力、麻木等临床症状的变化作为次要终点。结果治疗结束后,患者调节性T细胞CD4^+CD25^+、CD8^+CD28^-细胞较治疗前明显降低(P<0.05),细胞毒T细胞CD8^+CD28^+数量较治疗前明显升高(P<0.05);除疼痛外,患者乏力、耳鸣、麻木、食欲不振、睡眠障碍、腹部不适、小便异常等症状明显改善(P<0.05)。结论益气活血解毒方能够明显改善晚期卵巢癌的免疫抑制,提高患者的生活质量。
基金Supported by National Natural Science Foundation of China(NSFC)-funded Project:the Mechanisms of Tailored Immunotherapy of Yiqi Huoxue Jiedu Decoction Modulating T Regulatory Cells at the Level of the Tumor Microenvironment and Inherited Single Nucleotide Polymorphisms in Advanced Ovarian Cancer(No.81473566).
文摘OBJECTIVE:To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction(YHJD)on patients with advanced epithelial ovarian cancer(EOC).METHODS:All 330 enrolled participants diagnosed with stageⅢc EOC were randomly divided into two groups that received YHJD or a placebo.The primary end point was health-related quality of life(HRQL)measured by the functional assessment of cancer therapy-ovary cancer(FACT-O)questionnaire.The secondary end point was progression-free survival(PFS).RESULTS:A total of 299 participants completed the trial with 153 and 146 in YHJD and control groups,respectively.After 6 months of treatment,YHJD increased physical wellbeing(PWB),functional wellbeing(FWB),additional concerns(AC),and the trial outcome index(TOI)(P<0.05)by various degrees compared with the baseline.YHJD also had notable advantages over the placebo at 3 and 6 months in terms of PWB,FWB,AC(P<0.05),and TOI(P<0.01).In addition,YHJD had a significant advantage in terms of PFS compared with the placebo(21 vs18 months,P<0.05).No adverse events were reported.CONCLUSION:YHJD is an effective and safe choice as a complementary therapy to improve HRQL and prolong PFS of stageⅢc EOC patients.
